Source:http://linkedlifedata.com/resource/pubmed/id/18789115
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0019063,
umls-concept:C0030705,
umls-concept:C0032539,
umls-concept:C0036983,
umls-concept:C0041485,
umls-concept:C0078058,
umls-concept:C0225326,
umls-concept:C0332293,
umls-concept:C0439851,
umls-concept:C1171892,
umls-concept:C1185738,
umls-concept:C1552596,
umls-concept:C1749467,
umls-concept:C1947931
|
pubmed:issue |
4
|
pubmed:dateCreated |
2008-9-15
|
pubmed:abstractText |
Sepsis is characterized by a systemic inflammatory response to a microbial pathogen. In sepsis, capillary permeability is a tightly regulated feature of microcirculation in all organ beds and is fundamentally altered. We investigated the vascular endothelial growth factor (VEGF) level as a vascular permeability factor and the soluble fms-like tyrosine kinase-1 (Flt-1) level as an antagonist of the VEGF receptors. Serum VEGF and soluble Flt-1 levels in 21 patients with septic shock, who were treated with direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX), were measured by enzyme-linked immunoassay. The VEGF and the soluble Flt-1 levels were more elevated in patients with septic shock than in controls. Between 14 survivors and 7 non-survivors, there was no significant difference in VEGF level before the DHP-PMX therapy, but the soluble Flt-1 level of survivors was significantly lower than that of non-survivors. Although there was no significant difference between starting and ending VEGF levels in survivors, in non-survivors the VEGF level at the end of DHP-PMX therapy was significantly lower than that at the start. In survivors, the soluble Flt-1 level at the end of DHP-PMX therapy was significantly lower than that at the start. On the other hand, in non-survivors, there was no significant difference between the ending and starting soluble Flt-1 levels. The soluble Flt-1 level may be a suitable marker of disease severity and mortality.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/FLT1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Polymyxin B,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1744-9987
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
285-91
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:18789115-Aged,
pubmed-meshheading:18789115-Anti-Bacterial Agents,
pubmed-meshheading:18789115-Biological Markers,
pubmed-meshheading:18789115-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:18789115-Female,
pubmed-meshheading:18789115-Hemoperfusion,
pubmed-meshheading:18789115-Humans,
pubmed-meshheading:18789115-Male,
pubmed-meshheading:18789115-Middle Aged,
pubmed-meshheading:18789115-Polymyxin B,
pubmed-meshheading:18789115-Severity of Illness Index,
pubmed-meshheading:18789115-Shock, Septic,
pubmed-meshheading:18789115-Survivors,
pubmed-meshheading:18789115-Vascular Endothelial Growth Factor A,
pubmed-meshheading:18789115-Vascular Endothelial Growth Factor Receptor-1
|
pubmed:year |
2008
|
pubmed:articleTitle |
Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column.
|
pubmed:affiliation |
Department of Nephrology, Mito Saiseikai General Hospital, Mito, Japan. itaruebi@yahoo.co.jp
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial
|